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Perforin gene (PRF1) transcription regulates
perforin expression in NK cells and CTL. Here
we identified the locus-wide ensemble of cis-
acting sequences that drivesPRF1 transcription
physiologically. By using chromosome transfer,
we revealed that de novo activation of a silent
PRF1 locus was controlled by a 150 kb domain
comprised of 16 DNase I hypersensitive sites
(DHSs). These cis-acting sequences included
a locus control region (LCR) and conferred de-
velopmentally appropriate and lineage-specific
expression of human perforin from BAC trans-
genes. The LCR included four distal DHSs that
were required for perforin expression from its
natural locus, and their engineered deletion
from the PRF1 BAC transgene abolished LCR
function and led to rapid gene silencing. Thus,
LCR function is central for regulating the devel-
opmental and activation-specific PRF1 pro-
moter activity characteristic of NK cells and
CTL.
INTRODUCTION
The innate and adaptive immune response to intracellular
infections and malignancy depends critically on lympho-
cyte-mediated cytotoxicity. The predominant mechanism
used by lymphocytes to kill infected or malignant cells in
the host involves exocytosis of granules containing per-
forin and a family of serine esterases known as granzymes
(Henkart, 1985; Kagi et al., 1996). Perforin expression is
required for granule-mediated cytotoxicity, ensuring tar-
get cell entry of the granzymes, which ultimately induce
apoptosis (Keefe et al., 2005). The mechanism of gran-
ule-mediated cytotoxicity and its biological significance
is well established. However, current understanding of
the genetic and epigenetic programming of genes thatcode for cytotoxic effector proteins, such as perforin, is
critically underdeveloped (Glimcher et al., 2004).
Perforin is primarily expressed in NK cells, antigen-ex-
perienced CD8+ T cells, and gd T cells, but it can also be
expressed in subpopulations of CD4+ T cells and NKT
cells (De Rosa et al., 2004; Grossman et al., 2004; Gum-
perz et al., 2002; Kagi et al., 1996; Nakata et al., 1992). Ma-
ture NK cells uniformly express perforin in all cells by virtue
of constitutive gene transcription and are spontaneously
lytic (Nakata et al., 1992; Salcedo et al., 1993), whereas
perforin expression by peripheral T cells requires gene ac-
tivation (Lu et al., 1992; Zhang et al., 1999). PRF1 tran-
scription is a central mechanism that determines perforin
expression in CTL and NK cells, although perforin protein
is processed prior to storage in cytotoxic granules, sug-
gesting that additional regulation may exist (Garcia-Sanz
and Podack, 1993; Lu et al., 1992; Uellner et al., 1997;
Zhang et al., 1999).
Despite perforin’s critical role in vivo (Kagi et al., 1996;
Stepp et al., 1999), the key cis-acting regulatory regions
that control PRF1 transcription in NK cells and CD8+ T
cells have not been identified. Analysis of the promoter re-
gion in vitro indicates that it preferentially mediates tran-
scription in perforin-expressing cell lines (Lichtenheld
and Podack, 1992; Youn et al., 1996; Zhang and Lichten-
held, 1997). In transgenic mice, however, reporter genes
driven by the mouse perforin (Prf1) promoter are subject
to position effect variegation (PEV), and unlike the endog-
enous Prf1 gene, the transgenic promoter does not drive
constitutively elevated expression in NK cells relative to
T cells nor does it respond to activation in CTL (Festen-
stein et al., 1996; Lichtenheld et al., 1995). Subsequent
studies identified two classical enhancers 15 kb and
1 kb upstream of PRF1 that respond to T cell stimulation
(Zhang et al., 1999). Nevertheless, large genomic PRF1
clones that contained both enhancers and the promoter
are only expressed in a subset of transgenic mice, and
in those, expression was only 5% of that expressed
from the endogenous Prf1 gene (Zhang et al., 1999).
Thus, critical regulatory domains are likely to reside be-
yond the 45 kb analyzed by these transgenes.Immunity 26, 29–41, January 2007 ª2007 Elsevier Inc. 29
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LCR of the Perforin GeneIn this report, we identified the essential distal regulatory
regions in the mouse and human perforin genes. With a
combination of mega-DNaseI hypersensitivity analysis
(MDHA) (Pipkin and Lichtenheld, 2006) and microcell-
mediated chromosome transfer (MMCT), we discovered
that 16 DNase I hypersensitive sites (DHSs) delineate
a 150 kb territory that controlled PRF1 expression. Four
of the 16DHSswere containedwithin a distal locus control
region (LCR) and were required for perforin expression.
The transgenic function of the PRF1 territory was evalu-
ated in an embryonic stem (ES) cell-based differentiation
system that recreates NK and T lymphoid development
(Desbaillets et al., 2000; Schmitt et al., 2004). Deletion of
the LCR from a PRF1 BAC transgene abolished PRF1
expression and led to rapid gene silencing. Together,
our results defined a comprehensive network of regulatory
domains controlling PRF1 expression and demonstrated
that a distal 50 cluster was essential for biological expres-
sion of perforin in cytotoxic lymphocytes.
RESULTS
Chromosome Transfer Activates PRF1
Transcription De Novo
Human chromosome 10, bearing a silent copy of the PRF1
allele, was transferred from fibroblasts into a CTL cell line
via microcell-mediated chromosome transfer, a strategy
to study the function of cis-acting domains that control
gene activation and silencing (Rollini and Fournier, 1999;
Schubeler et al., 2000). Micronuclei were isolated from
HA(10)A, mouse fibroblasts that maintain one copy of
a neomycinr (neor)-tagged human chromosome 10, and
were fused to the rodent CTL cell line SAM-19 (Pershouse
et al., 1993; Zhang et al., 1999). Clones bearing human
chromosome 10 were isolated by selection in G418 and
characterized by fluorescent in situ hybridization (FISH)
and genomic Southern blot analysis (Figures 1A and 1B).
Seven clones designated as CTL(10) maintained one or
two copies of the human transchromosome with intact,
unrearranged PRF1 alleles. In all clones, expression from
the transchromosomal PRF1 was activated and its ex-
pression was regulated by IL-2 stimulation, unlike that of
its downstream neighbor PALD (Figures 1C and 1D). How-
ever, in contrast to previously analyzed transgenes that
were expressed at subphysiological amounts (Zhang
et al., 1999), physiological amounts were expressed from
the transchromosomal PRF1 allele, as compared to ex-
pression from the endogenous Prf1 gene, indicating that
all essential PRF1-specific regulatory regions were acti-
vated after chromosome transfer (Figure 1E). PRF1 was
not coregulated with its neighboring genes: ADAMTS14
was expressed in the fibroblasts, but was silenced after
transfer into the CTL, while PALD was expressed in the fi-
broblasts before transfer and in the CTL after transfer
(Figure 1F; see Figure 2A for locus map). Thus, PRF1 ex-
pression appeared to be controlled by regulatory regions
that were distinct from those that controlled ADAMTS14
and PALD.30 Immunity 26, 29–41, January 2007 ª2007 Elsevier Inc.Delineation of the Regulatory Domains of PRF1
To determine the cis-regulatory domains that mediated
transcriptional reprogramming of PRF1, we analyzed
230 kb surrounding PRF1 (Figure 2A) via MDHA (Pipkin
and Lichtenheld, 2006). In donor fibroblasts, several prom-
inent DHSs were detected over ADAMTS14 and PALD
(Figure 2B and see Table S1 in the Supplemental Data
available online). In 100 kb surrounding PRF1, seven
DHSs were noted in fibroblasts, whereas after reprogram-
ming in the CTL, 10 DHSs (DHSs 6, 7, 8, 10, 11, 12, 13, 14,
15a, and 16) were activated de novo. Conversely, near the
ADAMTS14 gene, four DHSs (DHSs 1, 3, 5, and 9) that
were present in fibroblasts were extinguished after chro-
mosome transfer into the CTL (Figures 2B and 2C and
Figure S1). Nevertheless, all DHSs present in fibroblasts
across the PALD gene were also present after chromo-
some transfer into the CTL. Three DHSs near the 50 end
of PALD (DHSs 20, 21, 22) appeared to be PALD specific
because they do not form in cells that do not express
PALD, even when PRF1 is expressed (Pipkin and Lichten-
held, 2006). However, DHSs 2 and 4 upstream of PRF1,
and DHSs 17, 18, 19 downstream of PRF1, were present
before and after chromosome transfer, and they flanked
all DHSs that had been induced across PRF1 in the CTL;
they have been detected in other cell types regardless of
expression from PRF1 or its neighbors, and so might have
functioned as nonspecific organizers of the locus. There-
fore, we hypothesized that DHSs 2 and 19 represented
the potential 50 and 30 termini of an active PRF1 chromatin
domain (Labrador and Corces, 2002; Saitoh et al., 2000).
Similar to the human PRF1 locus, the mouse perforin
(Prf1) gene is found on mouse chromosome 10 and is lo-
cated between the mouse Adamts14 and Pald genes
(Figure 3A). To determine whether the specific long-range
chromatin structure of PRF1 occurs in primary CTL, we
compared the locus in effector T lymphocytes differenti-
ated from purified CD8+ and CD4+ T cells from naive
mice. After differentiation, CD8+ CTL expressed greater
than 20-fold more Prf1 mRNA than the Th1 effector cells
(Figure 3B), yet both CTL and Th1 cells manifested the
same DHSs in promoter, intronic, and flanking proximal
sequences of Prf1. However, two distal DHSs (mouse
DHSs 3 and 9) formed specifically in CTL (Figure 3C). Pre-
vious studies in transgenic mice (Lichtenheld et al., 1995;
Zhang et al., 1999) show that the perforin promoter and
proximal regulatory sequences, from either the mouse or
human locus, can not promote physiologically high ex-
pression of perforin in CTL relative to Th cells (Figure 4A).
Because mouse DHS 3 was near conserved noncoding
sequences (CNS) that corresponded with the human
DHSs 4–8 identified in CTL(10) (Figure S2), we hypothe-
sized that these distal regulatory regions accounted for
the high perforin expression in CD8+ T cells relative to
CD4+ T cells.
DHSs 2–19 Promote Physiological Amounts
of Transgenic PRF1 Expression
To examine whether human DHSs 2–19 were sufficient to
drive PRF1 expression, a bacterial artificial chromosome
Immunity
LCR of the Perforin GeneFigure 1. Chromosome Transfer Activates Transchromosomal PRF1 Loci
(A) FISH analysis of donor cells (fibroblast), recipient cells (CTL), and one of the transchromosomal clones designated as CTL(10). Metaphase spreads
were hybridized with human chromosome 10 paint (pink) and counterstained with DAPI (blue).
(B) Genomic Southern blot analysis of the donor and recipient cells and seven CTL(10) clones compared to human T cells (2n human). No rearrange-
ments of the PRF1 loci were detected in >150 kbwith four hybridization probes (representative shown). The copy numbers of the human perforin gene
are indicated. They were determined in relation to the donor cells (1 copy) after normalizing the data for the endogenous mouse Prf1 gene and were
consistent with the FISH analysis.
(C) Transchromosomal and endogenous perforin mRNAs (human versus mouse) are equally expressed in CTL(10) clones. The northern blot shown
analyzes the clones after IL-2 activation. Species-specific hybridization controls included the human NK-like lymphoma YT (control) and the activated
rodent recipient cells (CTL).
(D) The IL-2 response of the transchromosomal perforin (PRF1) and paladin (PALD) mRNAs was assayed in the CTL(10) clones by northern blot
analysis.
(E) Quantification of perforin expression in each clone from (C) (left) and average human perforin expression in all clones from (D) (right). The phos-
phorimagery data were corrected for gene copy numbers and the activity and hybridization efficiencies of each species-specific probe. Error bars are
standard deviation, and the asterisk indicates p < 0.005 according to Student’s t test.
(F) Transchromosomal PRF1 and its neighboring genes, ADAMTS14 and PALD, are independently expressed after chromosome transfer. Donor and
recipient cells (fibroblast and CTL) and one representative CTL(10) clone were examined by northern blot analysis.(BAC) that spanned DHSs 2–19 was stably transfected
into the CTL cell line (Figure 4A). Seven independently de-
rived transgenic cloneswere isolated that carried from1 to
10 intact copies of the transgene (Figure 4B). We used the
human perforin-specific monoclonal antibody dG9, whichdoes not crossreact with mouse perforin, to assess per-
forin expression from the transgenic PRF1 allele at the sin-
gle-cell level by intracellular staining (Schlesinger and
Cheng, 1994). Human perforin expression was uniform
among all cells in each clone, and there was a linearImmunity 26, 29–41, January 2007 ª2007 Elsevier Inc. 31
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LCR of the Perforin GeneFigure 2. Chromosome Transfer Induces Locus-Wide Chromatin Remodeling of PRF1
(A) Map of PRF1 and its neighboring genes, their exons, and their transcriptional orientations. Also shown are the probes and restriction sites used for
MDHA in (B).
(B) MDHA of donor cells (fibroblast) and one recipient CTL(10) clone. Nuclei were purified from IL-2-activatedCTL(10) cells and treatedwith increasing
DNase I concentrations (wedges). Numbered arrows indicate DHSs. Each blot represents two independent experiments, including independent nu-
clei preparations. Most DHSswere confirmedwith probes hybridizing to the reciprocal end of the analyzed fragments. DHSs 1 and 2 were detected in
a 26 kb Pac I to Mss I fragment (Figure S1).
(C) Summary of the remodeled chromatin and reprogrammed expression. ‘‘ON’’ versus ‘‘OFF’’ indicates mRNA expression for each gene (see
Figure 1F).correlation between the mean fluorescent intensity (MFI)
of human perforin expression and PRF1 transgene copy
number (Figures 4C and 4D). Furthermore, the expression
amount per transgene copy in each clonewas the same as
that expressed by the transchromosomal allele (Fig-
ure 4D). To address whether these amounts were compa-
rable to what is expressed in primary CTL, human CD8+ T
cells were activated with robust signals in vitro and ana-
lyzed. Expression from the endogenous PRF1 locus in
the primary human CTL was similar to that from the trans-
gene or the transchromosome at both the mRNA and
protein amounts in the CTL model (Figure 4E). Finally, ex-
pression of the DHS 2–19 PRF1 transgene was not core-32 Immunity 26, 29–41, January 2007 ª2007 Elsevier Inc.gulated with expression from the linked Pgk-neor gene
(Figures S3 and S4; Rollini et al., 2000). Therefore, we con-
cluded that DHSs 2–19 collectively mediated copy
number-dependent, position-of-integration-independent
transgenic PRF1 expression, at physiological amounts,
in the CTL model.
DHSs 2–19 Drive Lineage-Appropriate Expression
of PRF1
Results from the CTL model suggested that the PRF1
transgene contained elements sufficient for LCR activity.
However, cell line-based experiments do not recapitulate
the control of gene expression during development,
Immunity
LCR of the Perforin GeneFigure 3. Primary Mouse CTL Specifically Program the Prf1 Locus
(A) Map of DHS formation across the Prf1 locus and its neighboring genes in primary Th1 cells versus CTL. The CTL-specific DHSs 3 and 9 are in-
dicated in red. Also shown are the probes and restriction sites used for MDHA in (C).
(B) Northern blot analysis of mouse perforin mRNA expression. Total RNA was extracted from Th1 cells and CTL at the time when the nuclei were
isolated for (C).
(C) MDHA of primary Th1 cells versus CTL. DHS formation is indicated by numbered arrows and is summarized in (A). Data for the 95 kb Pac I fragment
are not shown.which, by definition, is a prerequisite for LCR function
(Grosveld et al., 1987). Therefore, we used the OP9/ES
cell differentiation system (Cho et al., 1999; Schmitt
et al., 2004) to determine whether the DHS 2–19 transgene
could activate and repress PRF1 appropriately during in
vitro hematopoiesis. The ES cell clone 129-B6 G4 (Nagy
et al., 1993) was stably transfected, and two clones bear-
ing one versus four intact copies of the DHS 2–19 trans-
gene (Figure 5A) were used for in vitro differentiation ex-
periments (Figure 5B; Cho et al., 1999; Schmitt et al.,
2004). The transgene was not expressed in myeloid line-
ages (Ter119+ or MHC class II+) or in developing B lym-
phocytes (CD19+) (Figure 5C, and data not shown; Martin
et al., 2005). In contrast, all transgenic NK cells (NK1.1+)
constitutively expressed large amounts of human perforin
in analogy to primary NK cells, and the amounts of expres-sion paralleled the transgene copy numbers (Figure 5C,
right histograms). Human perforin from the PRF1 trans-
gene was not expressed in unstimulated ab T cells (Fig-
ure 5D). However, TCR and IL-2 stimulation induced ex-
pression of transgenic PRF1 in all mature single-positive
CD8+ T cells from both ES cell clones (Figure 5D, far right),
although transgenic protein expression amounts were not
correlated with transgene copy number (see Discussion).
Transgenic PRF1 was also expressed and upregulated
by IL-2 in a fraction of gd T cells derived from each ES
cell clone (Figure 5E), similar to what is observed during
the development of primary human gd T cells (De Rosa
et al., 2004). Taken together, 150 kb of the PRF1 locus
containing DHSs 2–19 drove copy number-dependent,
lineage- and stage-specific expression of transgenic
PRF1 during cytotoxic lymphocyte differentiation in vitro.Immunity 26, 29–41, January 2007 ª2007 Elsevier Inc. 33
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LCR of the Perforin GeneFigure 4. DHSs 2–19 Drive Copy Number-Dependent Transgene Expression at Physiological Amounts
(A) Alignment of DHS formation across PRF1 and its neighboring genes with the previously analyzed cosmid transgenes (Zhang et al., 1999) and the
BAC DHS 2–19 transgene analyzed here.
(B) Copy number and integrity of the DHS 2–19 transgenes. Transgenic CTL, untransfected CTL, and a CTL(10) clone with a single transchromosome
were compared by genomic Southern blot analysis. A representative blot from the analysis of more than 120 kb is shown.
(C) Copy number-dependent expression by DHS 2–19. Transgene expression was assessed in IL-2-stimulated DHS 2–19 transgenic CTL by flow
cytometry (see [D]). The mean fluorescence intensity (MFI) of each transgenic clone is plotted versus its copy number. Linear regression analysis
was calculated with an origin set to zero.
(D) Human perforin expression in four representative DHS 2–19 transgenic CTL clones (black) and their untransfected parents (gray) was assessed by
intracellular staining of human perforin with the mAb dG9. The MFI and copy number are indicated.
(E) Human perforin expression by transchromosomal CTL(10) and transgenic DHS 2–19 CTL is comparable to the expression of activated primary
human CTL (CD8+ T cells activated for 2 days with anti-CD3 and IL-2 then recultured in IL-2 for 4 additional days). Staining of the untransfected
CTL served as control for the transgenic clones while an isotype control was used for the primary CTL.DHSs 4–8 Are Required for Copy Number
Dependence and High PRF1 Expression
DNase I hypersensitivity analysis showed that the noncy-
totoxic Jurkat leukemia cell line formed some but not all
DHSs observed in the CTL(10) cells (Figure 6A) and ex-
pressed only 5% of the perforin mRNA expressed by
CTL(10) cells. Because Jurkat T cells didn’t form DHSs
6, 7, 8, 10, 11, and 15a, and because previous cosmid
transgenes lacking primarily the upstream DHSs (6, 7,
and 8) were not expressed physiologically (Figure 4A),34 Immunity 26, 29–41, January 2007 ª2007 Elsevier Inc.we removed DHSs 6, 7, and 8 from the DHSs 2–19 trans-
gene (Figure S3). Additionally, DHS 4 was deleted be-
cause it synergized with DHS 6 to enhance transcriptional
activity of the core PRF1 promoter in transient reporter
assays (M.E.P. and M.G.L., unpublished data). In three in-
dependent clones that stably maintained intact integra-
tions of theDDHS4–8 transgene (Figure 6BandFigure S3),
expression from the DDHS 4–8 transgenes in each clone
did not correlate with the transgene copy number of
each clone, and the average expression per copy of the
Immunity
LCR of the Perforin GeneFigure 5. DHSs 2–19 Regulate Developmentally Appropriate Perforin Expression
(A) Generation of DHS 2–19 transgenic ES cells (ESC). Genomic Southern analysis of two representative transgenic restriction fragments are shown to
document copy number and integrity of the transgenes. Clones used for in vitro differentiation are indicated by asterisks.
(B) Scheme for coculture conditions promoting NK, B, and T cell development on the OP9 or OP9-DL1 stroma.
(C) Transgenic human perforin expression by B cells (CD19+) and NK cells (NK1.1+) differentiated in vitro from ESC. Untransfected ESC (gray) and two
independent transgenic clones (black) were analyzed by intracellular staining and flow cytometry.
(D) Transgene expression is induced upon activation of in vitro differentiated single-positive CD8+ T cells sorted for high TCRb expression. The left
panel depicts human perforin expression in CD4+ or CD8+ ab T cells differentiated for 23 days from transgenic (black) and nontransgenic (gray) ESC.
The right panel depicts the CTL after CD3 plus CD28 activation.
(E) Transgenic perforin is expressed in gdT cells after their stimulation with IL-2.DDHS 4–8 transgene was nearly four times less than that
derived from the wild-type transgene (Figure 6C). Expres-
sion from the DDHS 4–8 transgenes was less uniform than
expression from the wild-type DHS 2–19 transgene and
was unstable between independent experiments (Fig-
ure 6B), suggesting PEV (Festenstein et al., 1996). More-
over, in the absence of G418, PRF1 expression was rap-
idly silenced from all DDHS but not wild-type transgenes
(Figure 6D, top versus bottom). This was not due to loss
of transgenic DNA (Figure S4). Thus, DHSs 4–8 were re-
quired to prevent PEV of PRF1 transgenes and to heritably
maintain their expression throughout successive cell
generations.
DHSs 4–8 Are Required for Perforin Expression
from Its Endogenous Locus
During the initial characterization of transchromosomal
CTL(10) clones, FISH and Southern blotting experimentsidentified one clone with a spontaneous translocation
within the PRF1 locus (Figure 7A). Expression of mRNA
from themutant transchromosomal PRF1 allele was unde-
tectable (Figure 7B), which was reminiscent of the pheno-
type caused by large deletions in the b-globin locus that
initially revealed the location of its LCR (Forrester et al.,
1990). Restriction enzyme mapping analysis showed
that the exons of PRF1 as well as their proximal upstream
and downstream sequences were normal on the mutant
allele. However, we discovered that the restriction pattern
upstream of15 kb on the mutant allele diverged from the
wild-type and that probes upstreamof this location did not
hybridize to DNA from the clone carrying themutant allele,
indicating that DHSs 4–8were absent (Figures 7C and 7D).
Thus, sequences upstream of 15 kb that included DHSs
4–8 were required to establish or maintain endogenous
PRF1 transcription, even in the presence of all other native
chromosomal regulatory sequences of PRF1.Immunity 26, 29–41, January 2007 ª2007 Elsevier Inc. 35
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LCR of the Perforin GeneFigure 6. DHSs 4–8 Are Required for LCR Function
(A) Summary of MDHA of PRF1 and its neighboring genes in CTL(10) versus Jurkat T cells. Note the indicated 20-fold difference in their expression of
PRF1mRNA. Also shown is the genomic span of the DHS 2–19 transgene and its derivative in which DHSs 4–8 have been deleted (DDHS 4–8). These
constructs are analyzed in (B)–(D).
(B) Comparison of transgenic perforin expression in the DDHS 4–8 BAC clones with perforin expression in a CTL(10) clone with a single copy (stan-
dard). Two independent experiments of cells cultured in the continuous presence of G418 are shown.
(C) DHSs 4–8 are required for copy number-dependent transgene expression. Transgenic perforin expression (measured in MFI) is plotted in relation
to the copy numbers for eachDDHS4–8 clone and three representative DHS 2–19 clones (left). Themean amount of perforin expression per transgene
copy is summarized (right; error bars indicate standard deviation). Similar results were obtained when comparing transgenic perforin mRNA
(Figure S4).
(D) DHSs 4–8 are required for stable and unvariegated transgene expression. The DHS 2–19 and the DDHS 4–8 clones were compared 4 weeks after
removal of G418 selection (see Figure S4 for mRNA analysis).36 Immunity 26, 29–41, January 2007 ª2007 Elsevier Inc.
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LCR of the Perforin GeneFigure 7. Characterization of a Transcriptionally Defective PRF1 Allele Is Consistent with the Role of DHSs 4–8 as an LCR
(A) FISH analysis of a mutant CTL(10) clone. The picture indicates that the human transchromosome was translocated to a rodent chromosome (com-
pare to Figure 1A).
(B) The mutant transchromosomal PRF1 allele is inactive. The expression by a wild-type PRF1 transchromosome (w) was compared with its mutant
allele (m) by northern blot analysis. The transchromosomal mRNA was undetectable from the mutant human allele even after >10-fold overexposure.
Note that the endogenous mouse perforin RNA was expressed equivalently in both clones.
(C) Genomic Southern blot analysis of transchromosomal wild-type (w) andmutant (m)PRF1 alleles. Regionswhere sequenceswere undetectable are
highlighted in red and those demonstrating an abnormal pattern are indicated by asterisks. Restriction enzymes: B, Bgl II; H, Hind III; K, Kpn I; P, Pac I.
(D) Map of the PRF1 locus summarizing restriction sites, probes and results of (C).
(E) Model for organization of the active chromatin domain of PRF1. The overlap of the transcriptional territories is explained in the Discussion.Immunity 26, 29–41, January 2007 ª2007 Elsevier Inc. 37
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LCR of the Perforin GeneDISCUSSION
The molecular basis of cytotoxic gene expression during
the development and activation of lymphocytes is poorly
understood. In this report, we characterized the ensemble
of regulatory domains in the human PRF1 gene that are
necessary and sufficient for its physiological expression.
Furthermore, we provided functional evidence that PRF1
and its neighboring genes are demarcated into distinct
transcriptional ‘‘territories’’ as summarized in Figure 7E.
By combining chromosome transfer and MDHA, we
sought to identify the active chromatin domain of PRF1,
a territory that contains all essential regulatory elements.
An active chromatin domain was originally defined in the
chicken b-globin locus as an extended region of open
chromatin with discrete boundaries (Hebbes et al.,
1994). However, genome-wide mapping of histone acety-
lation suggests that active domains are heterogeneous
and are better defined as islands of histone hyperacetyla-
tion that coordinately form over active regulatory sites,
such as LCRs, enhancers, and promoters, aspects of
a gene locus that are also effectively mapped as DHSs
(Bulger et al., 2003; Roh et al., 2005). Other regulatory el-
ements referred to as insulators may establish the bound-
aries of chromatin domains, and they are frequently iden-
tified in constitutive or ubiquitous DHSs (Labrador and
Corces, 2002; Saitoh et al., 2000).With these observations
as the logic for interpreting the formation of DHSs in the
chromosome transfer experiments, we propose that the
genomic interval fromDHS 2 toDHS19 constitutes the ac-
tive chromatin domain of PRF1. A similar array of DHSs
across Prf1 was also observed in primary mouse CTL.
In the human locus, DHSs 2 and 4 were present before
and after chromosome transfer. DHS 4 has been detected
in all cell types analyzed to date, independent of PRF1 or
ADAMTS14expression. ThismakesDHS4apotential can-
didate for a boundary that insulates the 50 end of PRF1.
Similarly, we anticipate that DHSs15, 17, 18, and19,which
also have been detected in all cells, include one or more
boundaries involved in insulating PRF1 and PALD. Be-
cause none of the DHSsdownstreamof DHS19 correlated
with PRF1 expression, we presume that the 30 end of the
PRF1 domain is located no farther than DHS 19. Con-
versely, we presume that the PALD gene territory ends
near DHS 15. The overlap of the PRF1-specific DHSs 15a
and 16 with the neighboring gene most likely reflects that
these individual domains arenotmerely organized in a con-
tiguous linear array in the nucleus, but rather that they form
a three-dimensional architecture (Patrinos et al., 2004).
The transgene experiments also functionally indicated
that DHSs 2–19 include insulators that protected PRF1
from neighboring loci and vice versa. In our constructs,
the 50 end of the DHS 2–19 transgene was physically
linked to a Pgk promoter driving the neomycin resistance
gene. Yet, neor mRNA expression was not correlated with
expression of perforin mRNA. Thus, the Pgk promoter was
not responsible for PRF1 gene activity and, reciprocally,
PRF1 regulatory sequences did not dictate expression
of neor.38 Immunity 26, 29–41, January 2007 ª2007 Elsevier Inc.The chromosome-transfer experiments defined DHSs
2–19 as the PRF1 territory, and analysis of this territory
indicated that it functioned autonomously in the context
of a BAC transgene, as shown both in a cell-culture model
of developed CTL and with ES cells that could be differen-
tiated into blood cell lineages. In the CTLmodel, the trans-
gene drove copy number-dependent and integration
site-independent expression at amounts equivalent to
those from the endogenous gene. During in vitro differen-
tiation of ES cells, the PRF1 transgene was expressed in
a lineage-specific manner, and constitutive PRF1 expres-
sion without PEV became established during NK cell de-
velopment. Because transgenic protein expression was
lineage specific, lacked PEV, and correlated with trans-
gene copy number in NK cells, we conclude the transgene
exhibits LCR function.
In ES cell-derived CD8+ T cells, transgenic PRF1was in-
duced upon stimulation with TCR and cytokine signals as
expected; however, the amount of transgenic perforin
protein did not appear to correlate with the copy number.
A likely explanation is that the transgene saturated the ca-
pacity of the cells to process and appropriately compart-
mentalize excess perforin derived from the transgene
(Bachmann et al., 1999; Uellner et al., 1997). Indeed,
only activated CTL clones derived from repeated in vitro
stimulation, such as our SAM-19 model, express perforin
protein amounts similar to NK cells (Nakata et al., 1992;
Ohkawa et al., 2001). By contrast, NK cells do not require
activation and naturally express much higher amounts of
perforin protein than CTL.
Compared to other genes that have been analyzed with
large BAC- or YAC-derived transgenes, DHSs 2–19 of
PRF1 functioned remarkably well. For example, b-globin
expression from single-copy YAC transgenes that contain
its LCR still exhibits a mild degree of PEV, and transgenic
reporter expression from the Th2 cytokine locus in a BAC
transgene is not entirely Th2 lineage restricted in trans-
genic lines with high copy number (Alami et al., 2000;
Lee et al., 2003). In contrast, expression from a single-
copy integration of the PRF1 transgene was uniform in
both the CTL cell line and ES-derived NK cells, and ex-
pression from multicopy integrations was not promiscu-
ously activated in noncytotoxic lineages.
Wesuggest thatDHSs4–8comprise theLCR. Theywere
required for copy number-dependent and physiological
amounts of transgenic PRF1 expression, to prevent PEV,
and, ultimately, to prevent PRF1 from being silenced in
the context of the DHS 2–19 transgene. Furthermore,
a spontaneous deletion in one transchromosome, which
removed a larger region containing DHSs 4–8 from the nat-
ural PRF1 locus, completely prevented perforin mRNA ex-
pression from its endogenous chromosomal locus. Based
on preliminary transgenic analysis, the isolated DHS 4–6
region is sufficient for at least one hallmark of LCR function,
position-of-integration-independent transgene expression
(M.G.L., unpublished data). The DHS 2–19 transgene also
included severalCNS thatwere not found to beDNase I hy-
persensitive in the CTL(10) clones (Mayor et al., 2000).
Therefore, additional regulatory domains that contribute
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might exist in vivo, but they apparently were dispensable
for the expression of PRF1 in the CTL model cell line.
Our data suggest that DHSs 4–8 control PRF1 promoter
function but not the long-range chromatin structure of the
PRF1 locus. Primary Th1 cells and Jurkat T cells remod-
eled most regulatory regions (including the promoter) but
expressed low amounts of perforin, correlating with lack
of DHSs in the LCR (Pipkin and Lichtenheld, 2006). This
implies that DHSs 4–8 are dispensable for coordinating
long-range chromatin remodeling, but that their activation
might be essential for elevating PRF1 transcription to
physiological amounts. Similarly, concise deletion of the
b-globin LCR from its endogenous locus indicates that
the LCR does not orchestrate locus-wide decondensation
of the chromatin structure in developing erythroid cells,
but is essential for increasing transcriptional rates of the
globin genes in committed cells (Epner et al., 1998).
Thus, we hypothesize the LCR of PRF1 ensures two bio-
logical outcomes. First, the LCR appears to drive physio-
logically high transcription in cytotoxic lymphocytes, pos-
sibly through direct interaction with the PRF1 promoter.
Second, the LCRmay facilitate assembly of the remaining
distal regulatory elements in an active chromatin hub
(ACH) (Patrinos et al., 2004), ensuring that these distal reg-
ulatory domains—for instance, the previously described
IL-2-controlled enhancers (Zhang et al., 1999)—respond
appropriately to environmental cues.
The delineation of the overall territory of PRF1 has im-
portant implications. Abnormalities in distal regulatory do-
mains identified in this report might underlie certain cases
of familial hemophagocytic lymphohistiocytosis, a lethal
human disorder that can be caused by perforin deficiency.
Currently, mutations in coding or splice-site sequences do
not account for all cases linked to PRF1, and thus, alter-
ations in distal regulatory regions could provide a molecu-
lar explanation (Stepp et al., 1999; Voskoboinik et al.,
2006). In addition, little is known of the transcription fac-
tors that control perforin. Although Sp-1, AP-1, MEF,
MITF, T-bet, and Eomesodermin have each been impli-
cated to function at the perforin promoter (Glimcher
et al., 2004), the perforin promoter itself is insufficient for
physiological regulatory function in transgenic mice (Lich-
tenheld et al., 1995). Our data here show that appropriate
PRF1 promoter function depends critically on its LCR, im-
plying that these transcription factors might regulate the
distal sequences identified in this study. Therefore, this
study establishes a framework to elucidate how transcrip-
tion factors coordinate the long-range regulation of the
perforin locus in humans and mice to establish the cyto-
toxic program in lymphocytes.
EXPERIMENTAL PROCEDURES
Cells, Mice, and Antibodies
HA(10)A is amouse fibroblast line that carries one copy of human chro-
mosome 10 that was marked with a neomycin resistance gene (Coriell
Cell Repository) andwas cultured in DMEMcontaining 10%FBS under
selectionwith 500 mg/ml G418. SAM-19was cultured as previously de-
scribed (Zhang et al., 1999). The bone marrow-derived stromal cellsOP9 and OP9-DL1 were maintained by culture in a-MEM containing
20%FCS and have also been described (Schmitt and Zuniga-Pflucker,
2002). The ES cell (ESC) line 129-B6 G4 was obtained from A. Nagy
(Mount Sinai Hospital, Toronto, Canada) and was cultured on irradi-
ated mouse embryonic fibroblasts in DMEM containing 15% FCS,
10 U/ml penicillin, 100 mg/ml streptomycin, 100 mg/ml gentamicin,
2 mM glutamine, 110 mg/ml sodium pyruvate, 50 mM 2-mercaptoetha-
nol, 10mMHEPES, and 1 ng/ml of leukemia inhibitory factor (LIF) (R&D
Systems). Mouse abTCRhiCD4CD8+ T cells from ESC-OP9-DL1 co-
cultures were sorted at day 21 and stimulated for 3 days with 10 mg/
ml of plate-bound aCD3 (clone 145-2C11) and 5 mg/ml of plate-bound
aCD28 (clone 37.51) followed by culture in 1000 U/ml rhIL-2. Cells
were sorted with a FACSDiVa (BD Biosciences) and were R99%
pure, as determined by analysis after sorting. CD8+ T cells from
6-week-old C57BL/6 mice were isolated by negative selection and
stimulated for 2 days with plate-bound aCD3 and aCD28, and then re-
cultured in 100 U/ml rhIL-2 for 4 additional days. CD4+ T cells were iso-
lated by positive selection and Th1 differentiation was performed as
described (Lee et al., 2004). All mice were maintained in specific path-
ogen-free barrier facilities and used according to protocols approved
by the CBR Institute for Biomedical Research and Harvard Medical
School animal care and use committees.
Quiescent purified human T cells (CD3+, CD16, HLA class II) from
the Blood and Tissue Banking Facility at the University of Miami Syl-
vester Comprehensive Cancer Center were cultured in IMDM contain-
ing 10% heat-inactivated FBS. 2 3 106/ml purified T cells were stimu-
lated for 2 days with plates coated with aCD3 (10 mg/ml) in media
containing 200 U/ml rhIL-2, before reculturing in the presence of
1000 U/ml rhIL-2. Flow cytometry was performed on a FACScalibur
(BD Biosciences) instrument as described (Schmitt and Zuniga-
Pflucker, 2002). The human perforin-specific monoclonal antibody
dG9 was purchased from Biolegend (San Diego, CA). Intracellular
staining for human perforin was performed with the Cytofix/Cytoperm
kit according to the manufacturer’s instructions.
Microcell-Mediated Chromosome Transfer
Chromosome transfer was performed as described with the following
modifications (Fournier, 1981).
Micronuclei Isolation
The donor cells HA(10)A were seeded on eight 2.43 7.5 cm bullets as
1 3 105 cells/cm2 in two round 150 cm2 tissue culture dishes in 70 ml
DMEM containing 10% FBS. The cultures were incubated for 18 hr be-
fore colcemid was added to a final concentration of 0.03 mg/ml fol-
lowed by incubation for an additional 44 hr. The arrested cells were
enucleated by placing two bullets back to back in capped 50 ml round
bottom polystyrene tubes containing 35 ml of prewarmed (37C) se-
rum-free DMEM containing 10 mg/ml cytocholasin B and centrifuging
at 27,000 3 g for 70 min in a prewarmed Sorvall SS-34 rotor (30C).
Pelleted micronuclei were gently resuspended in a final volume of 10
ml prewarmed (37C) serum-free DMEM and were sequentially filtered
through 8 mm, then 5 mm nucleopore filters. At each filtration step, al-
iquots were stained for 5 min in 0.25% acetoorecin prepared in PBS,
and micronuclei were quantified by phase-contrast microscopy.
Microcell Fusion
The recipient CTL model SAM-19 was harvested from exponentially
growing cultures and was washed with prewarmed serum-free
DMEM and adjusted to 1 3 106 cells/ml. Micronuclei were fused in
a 2.5:1 ratio in 25 ml final volume, by combining 15 ml of the recipients
with 10 ml micronuclei (3.75 3 106 microcells/ml) in 50 ml polypropyl-
ene conical tubes and incubating at room temperature for 10 min be-
fore pelletingmixture 15min at 20003 g and 38C in a swinging bucket
rotor. Copelleted micronuclei and recipient cells were fused by adding
1.5 ml 50% PEG (Sigma) drop wise, before thoroughly resuspending
pellet. After 60 s, the fusions were gently diluted with 28.5 ml pre-
warmed serum-free DMEM. Fusions were again harvested and recov-
ered overnight in 10 ml nonselective media for SAM-19 in T25 flasks.
The fusions were harvested and resuspended as 1.6 3 104 live cells/
ml in SAM-19 media supplemented to 1.8 mg/ml G418, and 200 ml ofImmunity 26, 29–41, January 2007 ª2007 Elsevier Inc. 39
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were picked between weeks two and four.
MDHA, Northern and Southern Blot Analysis, and Probes
for Hybridization Assays
Nuclei isolation, DNase I treatment, FIGE and Southern blot analysis,
and computation of DHSs were performed exactly as described with
5 3 107 nuclei/ml embedded in agarose plugs; standard genomic
Southern analysis used 107 cells embedded in 1% low-melting-point
agarose in PBS (Pipkin and Lichtenheld, 2006). For northern analysis,
total RNA was extracted from cells by TRIZOL (Invitrogen), according
to the manufacturer’s instructions. Southern and northern hybridiza-
tions, including probes, have been described (Pipkin and Lichtenheld,
2006). FISH analysis was performed with a human chromosome ten
paint (Vysis) according to standard procedures at the Medical Cytoge-
netics Laboratory at the University of Miami Miller School of Medicine.
Homologous and Site-Specific Recombination
A pgk-promoter-driven neomycin resistance gene was introduced into
the lox511 site of the BAC vector (pBACe3.6) by site-specific recombi-
nation (Wang et al., 2001). Deletions in the human PRF1 BAC were
generated with the l-Red recombinase machinery essentially as de-
scribed (Datsenko and Wanner, 2000). In brief, BAC hosts were
made conditionally proficient for homologous recombination by trans-
formation with pKD46. Targeting DNA containing kanr flanked by frt
sites was generated by PCR of the template plasmid pKD4 with
primers including 50 bp of human PRF1 sequence flanking DHSs 4–
8. 200 ng of gel-purified ampliconwas transformed into electrocompe-
tent BAC hosts preinduced with 6.6 mM L-arabinose, and colonies
were selected for kanamycin resistance. No kanamycin-resistant col-
onies were obtained in parallel transformations of uninduced BACs.
The kanr gene was excised by transformation of the FLP recombinase
expression plasmid pCP20. BAC DNA was isolated on Qiagen tips. 2L
cultures incubated 12–14 hr were processed with 100ml resuspension
buffer, 100 ml lysis buffer, and 100 ml neutralization buffer. Purified
BAC DNA was precipitated and redissolved in 10 mM Tris (pH 8.0)
and 0.1 mM EDTA at 4C with gentle motion overnight before quanti-
fication by spectrophotometry and FIGE analysis.
BAC Transgenesis
BACDNA for stable transfection was linearizedwith PI-SceI via a single
recognition site located in the BAC vector at a concentration of 100 mg/
ml with 1 U/mg of PI-SceI (NEB) in the manufacturer’s recommended
buffer for 16 hr at 37C. The DNA was purified by dialyzing (MWCO
50 kDa- SpectraPor) two times 1:40 into DMEM (GIBCO12430-054)
containing 70 mM spermine, 30 mM spermidine, and 50 mg/ml gentami-
cin for SAM-19. For transfection, 400ml of thedialyzedBACwasused to
resuspend and electroporate 107 exponentially growing SAM-19 cells
as described (Zhang et al., 1999). After transfection, the cells were res-
ted as 5 3 106 cells/ml in nonselective media in a T25 for 18 hr before
adjusting to 2 3 104 live cells/ml in media containing 1.8 mg/ml active
G418. 200 ml of cells per well were plated in flat-bottom 96-well plates.
G418r clones were picked between days 12 to 18. For ESC transfec-
tions, linearized BAC was dialyzed into serum-free ESCmedia supple-
mented with polyamines as above, and 400 ml of dialyzed BAC was
combined with 400 ml containing 107 ESC in the same media supple-
mented to 40% serum in 4 mm gap cuvettes for electroporation with
a BTX-600ECM with the following settings: V = 250 V, R = 186 U, C =
500 mF. The cuvettes were incubated on ice for 10 min before and after
electroporation. Cells were rested for 48 hr before selection was ap-
plied. After dialysis, the DNA was quantified by spectrophotometry
and theBACwas adjusted to a concentration of 50–80 mg/ml in theme-
dia. Integrity of the DNA after dialysis was quantified by FIGE analysis.
Supplemental Data
Supplemental Data include four figures and one table and can be found
with this article online at http://www.immunity.com/cgi/content/full/
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